Developing A Blood Test For Early Stage Non-Small Cell Lung Cancer
Research type
Research Study
Full title
Developing A Blood Test For Early Stage Non-Small Cell Lung Cancer
IRAS ID
157067
Contact name
S Popat
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Research summary
Lung cancer is the leading cause of cancer-related death worldwide, in part due to the majority of patients with advanced disease at diagnosis. The prognosis of non-small cell lung cancer (NSCLC) improves significantly if the disease is detected in its early stages and it is possible to remove all the cancer with surgery.
Blood-bourne markers of lung cancer have been sought for several years in an attempt to improve detection of early lung tumours. The increasing sensitivity of PCR and sequencing techniques to detect free DNA from cancer in the circulation – also known as circulating tumour DNA (ctDNA) – suggests that this may be a very specific marker of lung cancer.
In this study, we aim to investigate ctDNA in early stage resectable adenocarcinoma of the lung and to develop a new approach to identifying patients at high risk of relapse post surgery and patients who could benefit most from adjuvant platinum-vinorelbine chemotherapy.
REC name
London - Central Research Ethics Committee
REC reference
14/LO/1586
Date of REC Opinion
26 Sep 2014
REC opinion
Favourable Opinion